These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 12860733)
1. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Maillefert JF; Combe B; Goupille P; Cantagrel A; Dougados M Ann Rheum Dis; 2003 Aug; 62(8):764-6. PubMed ID: 12860733 [TBL] [Abstract][Full Text] [Related]
2. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Landewé RB; Boers M; Verhoeven AC; Westhovens R; van de Laar MA; Markusse HM; van Denderen JC; Westedt ML; Peeters AJ; Dijkmans BA; Jacobs P; Boonen A; van der Heijde DM; van der Linden S Arthritis Rheum; 2002 Feb; 46(2):347-56. PubMed ID: 11840436 [TBL] [Abstract][Full Text] [Related]
3. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Haagsma CJ; van Riel PL; de Jong AJ; van de Putte LB Br J Rheumatol; 1997 Oct; 36(10):1082-8. PubMed ID: 9374925 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA. Lie E; Uhlig T; van der Heijde D; Rødevand E; Kalstad S; Kaufmann C; Mikkelsen K; Kvien TK Rheumatology (Oxford); 2012 Apr; 51(4):670-8. PubMed ID: 22157597 [TBL] [Abstract][Full Text] [Related]
5. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs. Schipper LG; Fransen J; Barrera P; Van Riel PL Rheumatology (Oxford); 2009 Jul; 48(7):828-33. PubMed ID: 19458163 [TBL] [Abstract][Full Text] [Related]
6. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. Bergstra SA; Landewé RBM; Huizinga TWJ; Allaart CF Rheumatology (Oxford); 2017 Oct; 56(10):1721-1728. PubMed ID: 28957556 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Dougados M; Combe B; Cantagrel A; Goupille P; Olive P; Schattenkirchner M; Meusser S; Paimela L; Rau R; Zeidler H; Leirisalo-Repo M; Peldan K Ann Rheum Dis; 1999 Apr; 58(4):220-5. PubMed ID: 10364900 [TBL] [Abstract][Full Text] [Related]
8. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort. Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497 [TBL] [Abstract][Full Text] [Related]
9. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B; J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012 [TBL] [Abstract][Full Text] [Related]
10. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701 [TBL] [Abstract][Full Text] [Related]
11. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA; Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767 [TBL] [Abstract][Full Text] [Related]
12. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Nagashima M; Matsuoka T; Saitoh K; Koyama T; Kikuchi O; Yoshino S Clin Exp Rheumatol; 2006; 24(3):260-7. PubMed ID: 16870092 [TBL] [Abstract][Full Text] [Related]
13. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Capell HA; Madhok R; Porter DR; Munro RA; McInnes IB; Hunter JA; Steven M; Zoma A; Morrison E; Sambrook M; Wui Poon F; Hampson R; McDonald F; Tierney A; Henderson N; Ford I Ann Rheum Dis; 2007 Feb; 66(2):235-41. PubMed ID: 16926184 [TBL] [Abstract][Full Text] [Related]
14. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219 [TBL] [Abstract][Full Text] [Related]
15. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994 [TBL] [Abstract][Full Text] [Related]
16. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. Mary J; De Bandt M; Lukas C; Morel J; Combe B J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710 [TBL] [Abstract][Full Text] [Related]
17. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Heimans L; Akdemir G; Boer KV; Goekoop-Ruiterman YP; Molenaar ET; van Groenendael JH; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF Arthritis Res Ther; 2016 Jan; 18():23. PubMed ID: 26794605 [TBL] [Abstract][Full Text] [Related]
18. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Ferraccioli GF; Gremese E; Tomietto P; Favret G; Damato R; Di Poi E Rheumatology (Oxford); 2002 Aug; 41(8):892-8. PubMed ID: 12154206 [TBL] [Abstract][Full Text] [Related]
19. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344 [TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]